SUBSCRIBE
SUBSCRIBE

Tvardi Therapeutics

IN THE PRESS
Press Releases
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 27, 2025
 · 
5 min read
Press Releases
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2025
 · 
1 min read
Press Releases
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 13, 2025
 · 
5 min read
Press Releases
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
May 6, 2025
 · 
5 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
 · 
7 min read
Press Releases
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
April 14, 2025
 · 
5 min read
Press Releases
Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research
March 19, 2025
 · 
9 min read
Press Releases
Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
February 19, 2025
 · 
1 min read
Press Releases
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024
 · 
16 min read
Press Releases
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024
October 2, 2024
 · 
1 min read
Load More
JOBS